R&G PharmaStudies Co. Ltd. A
R&G PharmaStudies Co., Ltd. operates as a clinical trial outsourcing service provider in China and internationally. It provides drug clinical research and development integrated services. The company's services include clinical trial operation, clinical trial site management, biological sample testing, data management and statistical analysis, clinical trial consulting, and clinical pharmacology … Read more
R&G PharmaStudies Co. Ltd. A (301333) - Total Liabilities
Latest total liabilities as of June 2025: CN¥418.40 Million CNY
Based on the latest financial reports, R&G PharmaStudies Co. Ltd. A (301333) has total liabilities worth CN¥418.40 Million CNY as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
R&G PharmaStudies Co. Ltd. A - Total Liabilities Trend (2019–2024)
This chart illustrates how R&G PharmaStudies Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
R&G PharmaStudies Co. Ltd. A Competitors by Total Liabilities
The table below lists competitors of R&G PharmaStudies Co. Ltd. A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Piovan S.p.A
F:PV0
|
Germany | €321.49 Million |
|
Selamat Sempurna Tbk
JK:SMSM
|
Indonesia | Rp891.25 Billion |
|
Daewoong
KO:003090
|
Korea | ₩1.47 Trillion |
|
HYAC-U
NYSE:HYAC-UN
|
USA | $176.79 Million |
|
Thaifoods Group Public Company Limited
BK:TFG
|
Thailand | ฿25.73 Billion |
|
BW Energy Ltd
OL:BWE
|
Norway | Nkr1.48 Billion |
|
Guangxi Nanning Waterworks Co
SHG:601368
|
China | CN¥19.93 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down R&G PharmaStudies Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.52 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how R&G PharmaStudies Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for R&G PharmaStudies Co. Ltd. A (2019–2024)
The table below shows the annual total liabilities of R&G PharmaStudies Co. Ltd. A from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥500.09 Million | +56.69% |
| 2023-12-31 | CN¥319.17 Million | +10.31% |
| 2022-12-31 | CN¥289.35 Million | +20.73% |
| 2021-12-31 | CN¥239.66 Million | +20.20% |
| 2020-12-31 | CN¥199.38 Million | +1.15% |
| 2019-12-31 | CN¥197.12 Million | -- |